Merck & Company Inc (MRK)vsSupernus Pharmaceuticals Inc (SUPN)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
SUPN
Supernus Pharmaceuticals Inc
$41.64
-0.12%
HEALTHCARE · Cap: $2.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 7916% more annual revenue ($66.57B vs $830.44M). MRK leads profitability with a 4.8% profit margin vs -13.2%. SUPN appears more attractively valued with a PEG of 1.47. SUPN earns a higher WallStSmart Score of 52/100 (C-).
MRK
Hold36
out of 100
Grade: F
SUPN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for SUPN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Revenue surging 32.4% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : SUPN
The strongest argument for SUPN centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 32.4% demonstrates continued momentum. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : SUPN
The primary concerns for SUPN are Piotroski F-Score, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
MRK profiles as a value stock while SUPN is a hypergrowth play — different risk/reward profiles.
SUPN carries more volatility with a beta of 0.56 — expect wider price swings.
SUPN is growing revenue faster at 32.4% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
SUPN scores higher overall (52/100 vs 36/100) and 32.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Supernus Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?